Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 158

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 158
---
 median reduction in polyp burden of 17%.
Over the course of 12 months, there were four related Grade 3 or higher and one related SAE reported during the trial, and a 95% compliance
rate at 12 months. One patient was removed from the trial due to non-compliance. In summary, after 12 months’ treatment, eRapa appeared
safe and well-tolerated with a median 17% reduction in the total polyp burden at 12 months compared with baseline and an overall 75% non-progression
rate. The 89% non-progression rate and 29% median reduction in polyp burden in Cohort 2 is likely to be the preferred dosage regimen for
Phase 3.

| 80 |

Tolimidone Developments

On July 16, 2024, we announced Health Canada had
approved a Phase 2a dose confirmation trial of tolimidone in T1D. The study is an Investigator Initiated Trial to be conducted by the
University of Alberta. The trial will measure C-peptide levels (a marker for insulin) and HbA1c (a marker for blood glucose) after three
months compared with baseline and the number of hyperglycemic events initially in 12 patients across three dose groups. The trial may
be expanded in due course.

MTX110 Developments

On October 4, 2024, we announced
an update on progression free and overall survival in our Phase 1 trial of MTX110 in rGBM, also known as the MAGIC-G1 study. At that
time, patients 1 and 2 had deceased, with overall survival since the start of treatment of 12 months and 13 months, respectively. Patients
3 and 4 remained in post-study follow-up. Patient 3 had progression free survival of six months and overall survival of 13 months since
start of treatment. Patient 4 has not yet had confirmed progression and therefore had progression free and overall survival of 12 months
since start of treatment.

The Phase 1 study is an open-label,
dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by CED via implanted
refillable pump and catheter.

Our Strategy

In early 2023, we decided
to re-position the Company as therapeutics (as opposed to drug delivery) company and we began looking for additional assets to complement
our MT